OncoMatch/Clinical Trials/NCT07801235
HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)
Is NCT07801235 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for head and neck (hnscc).
This is an international multi-centre, non-inferiority phase III randomized controlled trial comparing concurrent chemoradiation with high dose cisplatin (Arm A) vs. hyperfractionated radiation therapy (Arm B) in patients with head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1 N1-2 M0, T2 N1-2 M0, T3 N0-2 M0 (other)
Excluded: Stage T1 N0 M0, T2 N0 M0
Clinical stage T1-2 N1-2 M0 or T3 N0-2 M0 (UICC/AJCC TNM 8th Edition). Excluded: cT1-2 N0 M0, cT4, cN3, cM1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: induction or neoadjuvant chemotherapy for the study cancer
Previous induction or neo-adjuvant chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Cannot have received: cisplatin (cisplatin)
any prior exposure to cisplatin is excluded
Cannot have received: radiation therapy to the head and neck
Previous RT to the head and neck
Cannot have received: neck dissection of at least 3 levels on either side
neck dissection of at least 3 levels on either side
Lab requirements
Blood counts
Hemoglobin > 8g/dL (the use of transfusion or other intervention to achieve hemoglobin ≥ 8 g/dL is acceptable) Platelet count of >100,000 cells/mm3. ANC of > 1500 cells/mm3.
Kidney function
Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula
Liver function
Total bilirubin < 2 X institutional upper limit of normal. AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal. Albumin ≥ 3.0 g/dL.
Adequate hematologic, hepatic, and renal function must be documented within 8 weeks prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07801235 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior induction or neoadjuvant chemotherapy for the study cancer, cisplatin, radiation therapy to the head and neck disqualifies patients from enrollment.
What disease stage is eligible?
Stage T1 N1-2 M0 or T2 N1-2 M0 or T3 N0-2 M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages